Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023
January 04, 2024 at 05:05 pm EST
Share
Ekso Bionics Holdings, Inc. provided revenue guidance for the fourth quarter and full year of 2023. Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million, compared to total revenue of $3.6 million in the fourth quarter of 2022.
Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million, compared to $12.9 million in 2022.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
EKSO BIONICS HOLDINGS, INC. 
